Pliant Therapeutics
Pliant Therapeutics reported revenue of $0 million in fiscal 2025. Free cash flow was −$129 million. The diluted share count rose 1.4%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Pliant Therapeutics lost money in fiscal 2025: a net loss of $149 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 201 | 331 | 494 | 356 | 191 |
| Debt incl. finance leases | 0 | 10 | 10 | 30 | 0 |
| Net debt (negative means net cash) | −201 | −321 | −484 | −326 | −191 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.1x | 0.0x |
| Interest coverage | — | −160.8x | −145.3x | −75.5x | −61.1x |
| Current ratio | 12.4x | 14.2x | 17.7x | 10.9x | 12.0x |
| Quick ratio | 12.4x | 14.2x | 17.7x | 10.9x | 12.0x |
Cash flow
Projections
Project Pliant Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Pliant Therapeutics shares on the open market, and 4 insiders sold $163,621, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 20, 2026 | Bernard CouliePresident and CEO, Director | Sold plan | 89,375 | $1.28 | $114,400 | Form 4 |
| Jan 20, 2026 | Keith Lamont CummingsChief Financial Officer | Sold plan | 24,002 | $1.28 | $30,723 | Form 4 |
| Jan 20, 2026 | Lily CheungChief Human Resource Officer | Sold plan | 7,534 | $1.28 | $9,644 | Form 4 |
| Jan 20, 2026 | Minnie KuoChief Operating Officer | Sold plan | 6,917 | $1.28 | $8,854 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 8 | 2 of 8 | 4 of 8 |
| Rule of 40 | −7,506.6% | — | — |
| Altman Z'' | 13.40 | −0.82 | −7.54 |
| Accruals ratio | −10.4% | −12.1% | −6.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | 4 of 8 | 2 of 8 | 4 of 8 |
Compare
Put Pliant Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Pliant Therapeutics | FY25 | — | — | — | — | — | 4 | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 57 | 42 | 8 | 10 | 2 | 0 | 0 |
| Revenue growth | — | −26.7% | −81.9% | 27.9% | −83.7% | −100.0% | — |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 47 | 66 | 78 | 97 | 128 | 169 | 109 |
| Operating income | −1 | −42 | −98 | −127 | −184 | −228 | −156 |
| Net income | −1 | −42 | −97 | −123 | −161 | −210 | −149 |
| Diluted EPS (US$) | −4.22 | −1.95 | −2.71 | −2.94 | −2.75 | −3.47 | −2.43 |
| Diluted shares (millions) | 2 | 21 | 36 | 42 | 59 | 60 | 61 |
| Cash flow | |||||||
| Cash from operations | −3 | −37 | −75 | −95 | −116 | −156 | −128 |
| Capital expenditure | 1 | 2 | 2 | 2 | 1 | 4 | 0 |
| Free cash flow | −4 | −39 | −77 | −96 | −117 | −159 | −129 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 10 | 23 | 44 | 38 | 26 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 103 | 277 | 201 | 331 | 494 | 356 | 191 |
| Debt incl. finance leases | — | — | 0 | 10 | 10 | 30 | 0 |
| Total assets | 119 | 296 | 221 | 351 | 512 | 397 | 225 |
| Total liabilities | 9 | 12 | 22 | 37 | 39 | 93 | 44 |
| Shareholders' equity | −76 | 283 | 199 | 313 | 474 | 304 | 181 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −2.2% | −99.6% | −1,288.1% | −1,313.4% | −11,654.8% | — | — |
| Net margin | −1.1% | −99.3% | −1,284.5% | −1,273.3% | −10,211.1% | — | — |
| Free cash flow margin | −6.5% | −92.8% | −1,022.1% | −995.3% | −7,422.9% | — | — |
| Rule of 40 (growth + FCF margin) | — | −119.5% | −1,104.0% | −967.4% | −7,506.6% | — | — |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −40.2% | −40.4% | −48.1% | −41.0% | −54.1% | −61.5% |
| Return on assets | — | −20.0% | −37.6% | −43.1% | −37.4% | −46.3% | −48.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — |